Krystal Biotech Inc (NASDAQ:KRYS) Sees Significant Growth in Short Interest

Krystal Biotech Inc (NASDAQ:KRYS) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 1,440,000 shares, an increase of 25.2% from the August 30th total of 1,150,000 shares. Currently, 13.4% of the shares of the company are sold short. Based on an average trading volume of 171,000 shares, the short-interest ratio is currently 8.4 days.

In related news, Director Daniel Janney sold 88,684 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $46.46, for a total value of $4,120,258.64. Following the transaction, the director now owns 35,131 shares in the company, valued at $1,632,186.26. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 34.30% of the company’s stock.

Large investors have recently bought and sold shares of the business. Bank of Montreal Can purchased a new stake in shares of Krystal Biotech during the second quarter worth $29,000. Tower Research Capital LLC TRC purchased a new stake in shares of Krystal Biotech during the second quarter worth $72,000. Strs Ohio purchased a new stake in shares of Krystal Biotech during the second quarter worth $92,000. AQR Capital Management LLC purchased a new stake in shares of Krystal Biotech during the second quarter worth $365,000. Finally, Wells Fargo & Company MN lifted its position in shares of Krystal Biotech by 3.1% during the second quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock worth $381,000 after acquiring an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 56.40% of the company’s stock.

Several research firms recently commented on KRYS. Chardan Capital upped their price objective on Krystal Biotech from $57.50 to $75.00 and gave the company a “buy” rating in a research note on Monday, June 24th. ValuEngine downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Goldman Sachs Group began coverage on Krystal Biotech in a research note on Tuesday, September 24th. They issued a “neutral” rating and a $60.00 price objective on the stock. HC Wainwright set a $59.00 price objective on Krystal Biotech and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, BidaskClub downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $60.67.

Shares of NASDAQ:KRYS traded up $1.22 during trading on Friday, hitting $37.41. 132,814 shares of the company were exchanged, compared to its average volume of 211,999. The company has a market cap of $622.47 million, a PE ratio of -38.57 and a beta of 1.00. The stock has a 50 day moving average of $41.80 and a 200 day moving average of $38.18. Krystal Biotech has a 52-week low of $14.70 and a 52-week high of $51.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 49.80 and a quick ratio of 49.80.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Sell-side analysts forecast that Krystal Biotech will post -1.47 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Further Reading: S&P 500 Index

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.